| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD20 |
| Clinical data | |
| Trade names | Gazyva, Gazyvaro |
| Other names | afutuzumab,[1] GA101 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous infusion |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 28.4 days |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6512H10060N1712O2020S44 |
| Molar mass | 146064.72 g·mol−1 |
  (what is this?) (verify) | |
Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer.[5][6] It was originated by GlycArt Biotechnology AG and developed by Roche.[citation needed]
- ^ WHO Drug Information, Vol. 23, No. 2, 2009 Proposed INN: List 101 Archived 3 March 2016 at the Wayback Machine, p 176
- ^ a b "Australian Product Information - Gazyva® (obinutuzumab)". Archived from the original on 8 January 2023.
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
- ^ a b Cite error: The named reference
FDA Gazyva labelwas invoked but never defined (see the help page). - ^ a b "Gazyvaro EPAR". European Medicines Agency. 5 October 2023. Archived from the original on 2 March 2021. Retrieved 5 October 2023.